How Bitter Taste Receptors Drive Drug Resistance in Cancer Cells (IMAGE)
Caption
Schematic model of the excretion of incorporated anticancer drugs from ABCB1 via the activation of TAS2Rs. Various anticancer drugs are incorporated into cancer cells, followed by severe cell damage (upper). These incorporated anticancer drugs are recognized by the intracellular TAS2Rs, leading to the enhanced action of ABCB1. The activated ABCB1 promotes the excretion of the drugs, namely reduced accumulation of drugs in the cells, resulting in the contribution to the anticancer drug resistance (lower left). Harmless blockers for TAS2Rs may be used as efficacious agents to attenuate the excretion of the incorporated drugs, leading to an increase in the sensitivity of the cells against anticancer drugs (lower right).
Credit
Okayama University of Science
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND